TRAILR4/TNFRSF10D/DcR2 Antibody (104918) [Unconjugated]

In the presence of the metabolic inhibitor actinomycin D, Recombinant Human TRAIL R4/TNFRSF10D Fc Chimera (Catalog # 633-TR) inhibits Recombinant Human TRAIL/TNFSF10 (Catalog # 375-TEC) induced cytotoxicity in the L‑929 mouse fibroblast cell line in a dose-dependent manner (orange line). Under these conditions, inhibition of Recombinant Human TRAIL/TNFSF10 (20 ng/mL) activity elicited by Recombinant Human TRAIL R4/TNFRSF10D Fc Chimera (90 ng/mL) is neutralized (green line) by increasing concentrations of Human TRAIL R4/TNFRSF10D Monoclonal Antibody (Catalog # MAB633). The ND50 is typically 0.3-1.8 µg/mL.

Flow cytometry studies of scFv-Fc-scTRAIL molecules and Fc-scTRAIL on Colo205 and HCT116 cells(A) Expression levels of EGFR, HER2, HER3, EpCAM, and TRAIL-receptors were investigated after treatment of the cells with medium or 250 ng/ml BZB for 16 h. (B) Serial dilutions of the molecules were analyzed. (C) 20 nM scTRAIL units were analyzed after preincubation of the cells with PBA or a 200-fold molar excess of the respective blocking antibody. Binding of Fc-scTRAIL was measured in the presence of all blocking antibodies separately and is here represented as the mean of blocking with all different antibodies. Bound molecules were detected via anti-FLAG-PE. relative MFI, relative median fluorescence intensity. Pairwise comparisons were performed by unpaired t test (two-tailed; *P 0.05). Image collected and cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.24379), licensed under a CC-BY license. Not internally tested by R&D Systems.

• Reactivity: Hu
• Applications: Flow, B/N, CyTOF-ready, ELISA(Cap)
• Clone: 104918
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated

TRAILR4/TNFRSF10D/DcR2 Antibody (104918) [Unconjugated] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human TRAIL R4/TNFRSF10D
  Ala56-His211
  Accession # Q9UBN6
• Specificity: Detects human TRAIL R4/TNFRSF10D in ELISAs and Western blots. In sandwich immunoassays, less than 5% cross-reactivity with recombinant human (rh) TRAIL R1, rhTRAIL R2, TRAIL R3, rhTRAIL, rhTNF‑ alpha , and rhTNF-beta is observed.
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Gene: TNFRSF10D
• Purity Statement: Protein A or G purified from ascites
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • CyTOF-ready
  • ELISA Capture (Matched Antibody Pair) 2-8 ug/mL
  • ELISA Detection (Matched Antibody Pair) 0.1-0.4 ug/mL
  • ELISA Standard (Matched Pair)
  • Flow Cytometry 2.5 ug/10^6 cells
  • Neutralization 0.04-0.2 ug/mL
• Application Notes: ELISA Detection: Human TRAIL R4/TNFRSF10D Biotinylated Antibody (Catalog number BAF633)
  Standard: Recombinant Human TRAIL R4/TNFRSF10D Fc Chimera (Catalog number 633-TR)

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for TRAILR4/TNFRSF10D/DcR2 Antibody (104918) [Unconjugated]

• CD264 antigen
• CD264
• DcR2
• DCR2decoy with truncated death domain
• Decoy receptor 2
• TNF receptor-related receptor for TRAIL
• TNF-related apoptosis-inducing ligand receptor 4
• TNFRSF10D
• TRAIL R4
• TRAILR4
• TRAIL-R4
• TRAILR4TRAIL receptor 4
• TRUNDDTRAIL receptor with a truncated death domain
• tumor necrosis factor receptor superfamily member 10D
• tumor necrosis factor receptor superfamily, member 10d, decoy with truncateddeath domain

Background

Human TRAIL R4, also called decoy receptor 2 (DcR2) and TRUNND (TRAIL receptor with a truncated death domain), is a type I, TNF R family transmembrane protein, which is a receptor for TRAIL (APO2 ligand). In the TNF superfamily nomenclature, TRAIL R4 is designated as TNFRSF10D. TRAIL R4 is unique among the TRAIL receptors in that its cytoplasmic domain contains a truncated consensus death domain motif. Binding of TRAIL R4 does not result in an apoptotic signal. Overexpression of TRAIL R4 can protect cells bearing TRAIL R1 and/or TRAIL R2 from TRAIL-mediated apoptosis. The human soluble TRAIL R4/Fc chimera neutralizes the ability of TRAIL to induce apoptosis.

1. Griffith, T.S. et al. (1998) Curr. Opin. Immunol. 10:559.
2. Pan, G. et al. (1998) FEBS lett 424:41.
3. Marsters, S.A. et al. (1997) Cur. Biol. 7:1003.
4. Degli-Esposti, M.A. et al. (1997) Immunity 7:813.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for TRAILR4/TNFRSF10D/DcR2 Antibody (MAB633)(18)

Publications using MAB633

• Najib Ben Khaled, Katharina Hammer, Liangtao Ye, Ahmed Alnatsha, Sebastian A. Widholz, Ignazio Piseddu et al. TRAIL Receptor Targeting Agents Potentiate PARP Inhibitor Efficacy in Pancreatic Cancer Independently of BRCA2 Mutation Status Cancers (Basel) 10/26/2022 [PMID: 36358659]
• Nivetha Krishna Moorthy, Oliver Seifert, Stephan Eisler, Sara Weirich, Roland E. Kontermann, Markus Rehm et al. Low-Level Endothelial TRAIL-Receptor Expression Obstructs the CNS-Delivery of Angiopep-2 Functionalised TRAIL-Receptor Agonists for the Treatment of Glioblastoma Molecules 12/14/2021 [PMID: 34946664]
• JD Yoo, SM Bae, J Seo, IS Jeon, SMP Vadevoo, SY Kim, IS Kim, B Lee, S Kim Designed ferritin nanocages displaying trimeric TRAIL and tumor-targeting peptides confer superior anti-tumor efficacy Sci Rep, 2020-11-17;10(1):19997. 11/17/2020 [PMID: 33203916]
• L Danish, D Imig, F Allgöwer, P Scheurich, N Pollak Bcl-2-mediated control of TRAIL-induced apoptotic response in the non-small lung cancer cell line NCI-H460 is effective at late caspase processing steps PLoS ONE, 2018-06-21;13(6):e0198203. 2018-06-21 [PMID: 29927992] (Flow Cytometry, Human)
• Yoshihiro Suzuki-Karasaki, Kyoko Fujiwara, Kosuke Saito, Miki Suzuki-Karasaki, Toyoko Ochiai, Masayoshi Soma Distinct effects of TRAIL on the mitochondrial network in human cancer cells and normal cells: role of plasma membrane depolarization Oncotarget 5/25/2015 [PMID: 26057632]
• Neumann S, Hasenauer J, Pollak N, Scheurich P Dominant negative effects of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 4 on TRAIL receptor 1 signaling by formation of heteromeric complexes. J Biol Chem, 2014-04-24;289(23):16576-87. 2014-04-24 [PMID: 24764293] (Flow Cytometry, Human)
• Tang X, Lu J, Tu H, Huang K, Fu R, Cao G, Huang M, Cheng L, Dai L, Zhang L TRAIL-engineered bone marrow-derived mesenchymal stem cells: TRAIL expression and cytotoxic effects on C6 glioma cells. Anticancer Res, 2014-02-01;34(2):729-34. 2014-02-01 [PMID: 24511006] (Flow Cytometry, Rat)
• TRAIL-engineered pancreas-derived mesenchymal stem cells: characterization and cytotoxic effects on pancreatic cancer cells. Cancer Gene Ther., 2012-07-06;19(9):652-8. 2012-07-06 [PMID: 22767216] (Flow Cytometry, Human)
• Zauli G, Rimondi E, Celeghini C, Milani D, Secchiero P Dexamethasone counteracts the anti-osteoclastic, but not the anti-leukemic, activity of TNF-related apoptosis inducing ligand (TRAIL). J. Cell. Physiol., 2010-02-01;222(2):357-64. 2010-02-01 [PMID: 19877156] (Flow Cytometry, Human)
• Stary G, Klein I, Kohlhofer S, Koszik F, Scherzer T, Mullauer L, Quendler H, Kohrgruber N, Stingl G Plasmacytoid dendritic cells express TRAIL and induce CD4+ T-cell apoptosis in HIV-1 viremic patients. Blood, 2009-08-18;114(18):3854-63. 2009-08-18 [PMID: 19690337] (Flow Cytometry, Human)
• Secchiero P, Melloni E, Corallini F, Beltrami AP, Alviano F, Milani D, D'Aurizio F, di Iasio MG, Cesselli D, Bagnara GP, Zauli G Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells. Stem Cells, 2008-09-04;26(11):2955-63. 2008-09-04 [PMID: 18772312] (Flow Cytometry, Human)
• Shankar S, Chen Q, Ganapathy S, Singh KP, Srivastava RK Diallyl trisulfide increases the effectiveness of TRAIL and inhibits prostate cancer growth in an orthotopic model: molecular mechanisms. Mol. Cancer Ther., 2008-08-01;7(8):2328-38. 2008-08-01 [PMID: 18723480] (Flow Cytometry, Human)
• Toscano F, Fajoui ZE, Gay F, Lalaoui N, Parmentier B, Chayvialle JA, Scoazec JY, Micheau O, Abello J, Saurin JC P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells. Oncogene, 2008-03-17;27(30):4161-71. 2008-03-17 [PMID: 18345033] (Flow Cytometry, Human)
• Weinmann L, Wischhusen J, Demma MJ, Naumann U, Roth P, Dasmahapatra B, Weller M A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ., 2008-01-18;15(4):718-729. 2008-01-18 [PMID: 18202704] (Flow Cytometry, Human)
• Barbarotto E, Corallini F, Rimondi E, Fadda R, Mischiati C, Grill V, Vaccarezza M, Celeghini C Differential effects of chemotherapeutic drugs versus the MDM-2 antagonist nutlin-3 on cell cycle progression and induction of apoptosis in SKW6.4 lymphoblastoid B-cells. J. Cell. Biochem., 2008-05-15;104(2):595-605. 2008-05-15 [PMID: 18092340] (Flow Cytometry, Human)
• Locklin RM, Federici E, Espina B, Hulley PA, Russell RG, Edwards CM Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis. Mol. Cancer Ther., 2007-12-07;6(12):3219-28. 2007-12-07 [PMID: 18065493] (Flow Cytometry, Human)
• Braun FK, Fecker LF, Schwarz C, Walden P, Assaf C, Durkop H, Sterry W, Eberle J Blockade of death receptor-mediated pathways early in the signaling cascade coincides with distinct apoptosis resistance in cutaneous T-cell lymphoma cells. J. Invest. Dermatol., 2007-05-10;127(10):2425-37. 2007-05-10 [PMID: 17495957] (Flow Cytometry, Human)
• Singh TR, Shankar S, Srivastava RK HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. Oncogene, 2005-07-07;24(29):4609-23. 2005-07-07 [PMID: 15897906] (Flow Cytometry, Human)

Bioinformatics

• Gene Symbol: TNFRSF10D
• Uniprot:
  • Q9UBN6()